Design Therapeutics, Inc.
NASDAQ:DSGNBiotechnology
+$0.19 today
- Market cap
- $606.42M
- Beta
- 1.66
- P/E (TTM)
- -10.7
- EPS (TTM)
- -$1.13
Volume 0.32M
Average 0.74M
DSGN EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Design Therapeutics, Inc.NASDAQ: DSGN
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$17.48M, compared with -$17.56M a year earlier. Trailing-twelve-month EBITDA was -$69.09M.
Context
- EBITDA grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 7 analysts of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -41.2% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$17.48M-10.3% QoQ
- Last fiscal yearDec 2025
- -$69.17M-41.2% YoY
- LTMMar 2026
- -$69.09M-24.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +0.4% | +100.0% | +99.6 pp |
| 1 year | -41.2% | +100.0% | +141.2 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (69.17M) USD
- Year-over-year change
- -41.2%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (69.17M) | -41.2% |
| FY2024 | 2024-12-31 | (48.99M) | +26.1% |
| FY2023 | 2023-12-31 | (66.33M) | -5.5% |
| FY2022 | 2022-12-31 | (62.84M) | -77.5% |
| FY2021 | 2021-12-31 | (35.4M) | — |
EBITDA vs competitors
How DSGN compares with its peers on the latest reported figures
- DSGN's LTM Mar 2026 EBITDA of -$69.09M is the 3rd highest of the 11 companies compared; the peer median is -$164.89M.
- Its year-over-year change of -24.3% is the 4th highest of 11, against a peer median of -71.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $173.52M | -79.4% | — | 17.2% | |
| LTM Mar 2026 | $124.95M | +217.3% | — | 5.7% | |
| LTM Mar 2026 | -$69.09M | -24.3% | — | — | |
| LTM Mar 2026 | -$74.74M | -18129.5% | — | — | |
| LTM Mar 2026 | -$75.99M | +22.0% | — | — | |
| LTM Mar 2026 | -$164.11M | -405.9% | — | 511.5% | |
| LTM Mar 2026 | -$165.68M | -74.6% | — | — | |
| LTM Mar 2026 | -$174.59M | -68.4% | — | 243.2% | |
| LTM Mar 2026 | -$190.1M | -38.9% | — | — | |
| LTM Sep 2026 | -$473.54M | -208.3% | — | 49.3% | |
| LTM Jun 2026 | -$495.35M | -20.6% | — | — | |
| Peer median (excluding DSGN) | -$164.89M | -71.5% | — | 49.3% | |
Competitors are the stored peer set for DSGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 466K | 537K | 596K | 622K |
| Gross Profit | 0 | (466K) | (537K) | (596K) | (622K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 24.78M | 48.61M | 57.06M | 44.35M | 59.13M |
| Selling, General & Admin | 11.05M | 18.98M | 21.13M | 18.03M | 20.34M |
| Operating Expenses | 35.83M | 67.13M | 77.65M | 61.79M | 78.85M |
| Depreciation & Amortization | 129K | 466K | 537K | 596K | 622K |
| EBITDA | (35.4M) | (62.84M) | (66.33M) | (48.99M) | (69.17M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (35.83M) | (67.59M) | (78.19M) | (62.38M) | (79.47M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 0 | 12.8M | 9.68M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 298K | 4.29M | 11.33M | 12.8M | 9.68M |
| Income Before Tax | (35.53M) | (63.31M) | (66.86M) | (49.59M) | (69.79M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (35.53M) | (63.31M) | (66.86M) | (49.59M) | (69.79M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.77) | (1.14) | (1.19) | (0.88) | (1.22) |
| EPS (Diluted) | (0.77) | (1.14) | (1.19) | (0.88) | (1.22) |
| Weighted Avg Shares | 45.94M | 55.71M | 55.98M | 56.59M | 57.33M |
| Weighted Avg Shares (Diluted) | 45.94M | 55.71M | 55.98M | 56.59M | 57.33M |
Design Therapeutics, Inc.
NASDAQ:DSGN
Intrinsic Alpha fair value
Locked
Current Price
$9.47
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.